PT  - JOURNAL ARTICLE
AU  - Natarajan, Harini
AU  - Crowley, Andrew R.
AU  - Butler, Savannah E.
AU  - Xu, Shiwei
AU  - Weiner, Joshua A.
AU  - Bloch, Evan M.
AU  - Littlefield, Kirsten
AU  - Wieland-Alter, Wendy
AU  - Connor, Ruth I.
AU  - Wright, Peter F.
AU  - Benner, Sarah E.
AU  - Bonny, Tania S.
AU  - Laeyendecker, Oliver
AU  - Sullivan, David
AU  - Shoham, Shmuel
AU  - Quinn, Thomas C.
AU  - Larman, H. Benjamin
AU  - Casadevall, Arturo
AU  - Pekosz, Andrew
AU  - Redd, Andrew D.
AU  - Tobian, Aaron A.R.
AU  - Ackerman, Margaret E.
TI  - SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy
AID  - 10.1101/2020.09.16.20196154
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.16.20196154
4099  - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20196154.short
4100  - http://medrxiv.org/content/early/2020/09/18/2020.09.16.20196154.full
AB  - Convalescent plasma has emerged as a promising COVID-19 treatment. However, the humoral factors that contribute to efficacy are poorly understood. This study functionally and phenotypically profiled plasma from eligible convalescent donors. In addition to viral neutralization, convalescent plasma contained antibodies capable of mediating such Fc-dependent functions as complement activation, phagocytosis and antibody-dependent cellular cytotoxicity against SARS-CoV-2. These activities expand the antiviral functions associated with convalescent plasma and together with neutralization efficacy, could be accurately and robustly from antibody phenotypes. These results suggest that high-throughput profiling could be used to screen donors and plasma may provide benefits beyond neutralization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, as well as extramural support from the National Institute of Allergy and Infectious Diseases (R01AI120938, R01AI120938S1 and R01AI128779 to A.A.R.T, NIH Center of Excellence in Influenza Research and Surveillance HHSN272201400007C to A.P. and T32AI102623 to E.U.P.), National Heart Lung and Blood Institute (K23HL151826 to E.M.B), National Cancer Institute (2 P30 CA 023108-41 to M.E.A.), National Institute of General Medical Sciences (P20-GM113132 BioMT Molecular Tools Core) Bloomberg Philanthropies (A.C.) and Department of Defense (W911QY2090012 to A.C. and D.S.). A.C. was supported in part by NIH grants AI052733, AI15207 and HL059842. S.E.B. is supported by NIH NIAID 2T32AI007363.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subject research was approved by both the Johns Hopkins University School of Medicine Institutional Review Board and the Dartmouth-Hitchcock Medical Center Committee for the Protection of Human Subjects. All participants provided informed written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code to reproduce analyses are available at (link pending).